These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 25592399)
21. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up. Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450 [TBL] [Abstract][Full Text] [Related]
23. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995 [TBL] [Abstract][Full Text] [Related]
24. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311 [TBL] [Abstract][Full Text] [Related]
25. The use of sunitinib in renal cell carcinoma: where are we now? Czarnecka AM; Szczylik C; Rini B Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613 [TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724 [TBL] [Abstract][Full Text] [Related]
28. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma. Shi HZ; Tian J; Chen X; Wang D; Li CL Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518 [TBL] [Abstract][Full Text] [Related]
29. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418 [TBL] [Abstract][Full Text] [Related]
30. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases. Makino K; Yoda K; Tomoishi J; Kume H BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941 [TBL] [Abstract][Full Text] [Related]
32. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Kim JH; Park I; Lee JL Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Yoo C; Kim JE; Lee JL; Ahn JH; Lee DH; Lee JS; Na S; Kim CS; Hong JH; Hong B; Song C; Ahn H Jpn J Clin Oncol; 2010 Oct; 40(10):980-5. PubMed ID: 20457723 [TBL] [Abstract][Full Text] [Related]
34. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma. Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206 [TBL] [Abstract][Full Text] [Related]
35. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860 [TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239 [TBL] [Abstract][Full Text] [Related]
38. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381 [TBL] [Abstract][Full Text] [Related]
39. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? Mir MH; Changal KH; Aziz SA; Bhat GM; Lone AR Int Urol Nephrol; 2016 Nov; 48(11):1811-1816. PubMed ID: 27448573 [TBL] [Abstract][Full Text] [Related]
40. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. Coelho RC; Reinert T; Campos F; Peixoto FA; de Andrade CA; Castro T; Herchenhorn D Int Braz J Urol; 2016; 42(4):694-703. PubMed ID: 27564279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]